3 Pharma Trends for 2024: All about market access
Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.
Our products
Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.
Discover key FDA & EMA drug approvals of 2024, breakthrough innovations, and market trends. Explore what these approvals reveal about the pharma industry's future.
Discover insights from 'Market Access 2025' on overcoming HTA and drug reimbursement challenges. Learn strategies to navigate evolving market access hurdles.
Revitalized US approvals and thriving innovation are positive signs for new medicines this year. However, our Launch Readiness 2024 guide shows that cost and value remain critical to launch success.
As market access barriers proliferate, digitally enabled alignment is key to optimising new drug uptake.
Our Launch Readiness 2023 report examines the prospects and challenges for new medicines entering the market in the shadow of COVID-19.
With COVID-19 driving innovation and agility, 2022 promises another rich crop of pharma launches. Closer cost-benefit scrutiny demands carefully differentiated value.
COVID-19 has intensified launch challenges facing new drugs. R&D pipelines and regulatory approvals continue to deliver innovation and commercial promise.
Pharmaceutical companies must embrace pioneering new product launch software if they really want to optimise launch readiness to capitalise on renewed innovation and R&D productivity.
Damaging constraints on patient access to medicines come from many quarters. Pharma companies must ensure that poorly co-ordinated and executed drug launches are not to blame.
TRiBECA Knowledge needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Notice.